A new study suggests that pediatric patients with beta-thalassemia major (BTM) may be at risk of both bleeding and thrombosis due to a derangement of hemostatic parameters that can exist apart from hepatic iron overload, and also that there may be a balance between these risks in patients at an...
Latest News
MISSISSAUGA, ON – GSK announced today that Health Canada has approved Blenrep (belantamab mafodotin for injection) in combination with bortezomib and dexamethasone, or in combination with pomalidomide and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of...
Consolidation therapy with blinatumomab was found to improve event-free survival and have less toxicity than chemotherapy in children with high-risk, first-relapse B-cell acute lymphoblastic leukemia (B-ALL), according to the results of a phase 3 trial (ClinicalTrials.gov Identifier: NCT02393859). The trial results were recently reported in JAMA. The trial enrolled 108 children with...
THOUSAND OAKS, Calif. – Amgen (NASDAQ:AMGN) today announced that data from a multicenter, randomized Phase 3 study evaluating the efficacy, safety and tolerability of BLINCYTO® (blinatumomab) compared with consolidation chemotherapy before allogeneic hematopoietic stem cell transplantation (alloHSCT) in pediatric patients with high-risk first-relapse B-cell precursor acute lymphoblastic leukemia (B-ALL) were published...
Since its early days in the mid-2000s, optogenetics, with its potential to activate neurons with light, emerged as a promising technique for restoring vision in blind patients. In recent years, at least two companies have announced the start of clinical trials to test optogenetics-based therapies in humans, and one of...
Carlene Knight would love to do things that most people take for granted, such as read books, drive a car, ride a bike, gaze at animals in a zoo and watch movies. She also longs to see expressions on people’s faces. “To be able to see my granddaughter especially —...
Ghent, Belgium – Researchers at the VIB-UGent Center for Medical Biotechnology have discovered a promising strategy to improve treatment responses in multiple myeloma patients by blocking a protein that plays a key role in drug resistance. The study, published in Pharmacological Research, offers a potential new strategy to improve outcomes...
Plymouth, UK – Drugs developed to fight blood and other cancers could also help improve the efficiency of radiotherapy in the most commonly diagnosed low-grade brain tumour in adults, a new study has found. Meningioma account for approximately 36% of all primary brain tumours. The majority are successfully treated by...
Boston, Mass. – Like a criminal entering a witness protection program, cancer cells can shed their past and take on a new identity. Detecting such an identity-switch is particularly challenging when metastatic castration-resistant prostate cancer (CRPC) advances from adenocarcinoma to neuroendocrine prostate cancer (NEPC), a very difficult cancer to treat....
Amsterdam, July 22, 2024 – To date Parkinson’s disease (PD) is diagnosed clinically and rather late in the course of the disease. There is an urgent need to find an objective, quantifiable biomarker for the diagnosis of this highly prevalent movement disorder. Researchers have now found initial evidence that a...